Physician profile
Alan K Rogers
NPI 1821037474
$5,132.29
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,492 · 2020: $170 · 2021: $657 · 2022: $849 · 2023: $1,505 · 2024: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,939.10 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $623.19 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $439.02 | 2019-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $438.26 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $424.42 | 2019-2024 | Farxiga, Airsupra |
| Abbvie INC. | $342.47 | 2019-2024 | Vraylar, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $272.97 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $234.71 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $211.29 | 2019-2023 | |
| Lilly USA, LLC | $207.31 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $187.55 | 2022-2023 | Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $169.04 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.44 | 2019-2024 | Trulance, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.41 | 2019-2024 | Jardiance |
| Almatica Pharma LLC | $97.34 | 2022-2023 | Loreev Xr |
| Nevro Corp. | $85.03 | 2019-2024 | Senza |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.